Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Br J Surg ; 105(11): 1480-1486, 2018 10.
Article in English | MEDLINE | ID: mdl-29893418

ABSTRACT

BACKGROUND: With the widespread use of endoscopy, small and low-grade type 3 gastric neuroendocrine tumours (NETs) are increasingly being detected. The clinicopathological features, biological behaviour and appropriate treatment strategy for these NETs remain unclear. METHODS: Patients with biopsy-proven gastric NET and a normal fasting serum gastrin level were identified from a prospectively maintained database. Clinicopathological features and long-term outcome of local resection for type 3 NETs were reviewed retrospectively and compared according to tumour grade. RESULTS: Some 32 patients with type 3 gastric NETs were included (25 patients with NET grade G1, 5 with G2 and 2 with G3). Pathological tumour size was 2·0 cm or less in 30 patients. All tumours were well differentiated, even G3 lesions, and all tumours but one were confined to the submucosal layer. G1 NETs were significantly smaller and had a significantly lower lymphovascular invasion rate than G2 and G3 NETs. Twenty-two patients with a G1 NET without lymphovascular invasion were treated with wedge or endoscopic resection. After a median follow-up of 59 (range 6-102) months, no patient with a G1 NET of 1·5 cm or smaller developed recurrence and one patient with a G1 NET larger than 1·5 cm had recurrence in a perigastric lymph node. Among seven patients with a G2 or G3 NET, two had lymph node metastasis and one had liver metastases. CONCLUSION: Low-grade type 3 gastric NET has non-aggressive features and a favourable prognosis. Wedge or endoscopic resection may be a valid option for patients with type 3 gastric G1 NET no larger than 1·5 cm without lymphovascular invasion.


Subject(s)
Intestinal Neoplasms/diagnosis , Neoplasm Grading/methods , Neuroendocrine Tumors/diagnosis , Pancreatic Neoplasms/diagnosis , Stomach Neoplasms/diagnosis , Adult , Aged , Biomarkers, Tumor/blood , Biopsy , Endoscopy, Gastrointestinal , Female , Follow-Up Studies , Gastrectomy/methods , Gastrins/blood , Humans , Intestinal Neoplasms/blood , Intestinal Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local , Neuroendocrine Tumors/blood , Neuroendocrine Tumors/surgery , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/surgery , Prognosis , Prospective Studies , Stomach Neoplasms/blood , Stomach Neoplasms/surgery , Time Factors
2.
Article in English | MEDLINE | ID: mdl-29024314

ABSTRACT

BACKGROUND: Integrated relaxation pressure (IRP) is a key metric for diagnosing esophagogastric junction outflow obstruction (EGJOO). However, its normal value might be different according to the manufacturer of high-resolution manometry (HRM). This study aimed to investigate optimal value of IRP for diagnosing EGJOO in Sandhill HRM and to find clinicomanometric variables to segregate clinically relevant EGJOO. METHODS: We analyzed 262 consecutive subjects who underwent HRM between June 2011 and December 2016 showing elevated median IRP (> 15 mm Hg) but did not satisfy criteria for achalasia. Clinically relevant subjects were defined as follows: (i) subsequent HRM met achalasia criteria during follow-up (early achalasia); (ii) Eckardt score was decreased at least two points without exceeding a score of 3 after pneumatic dilatation (variant achalasia); and (iii) significant passage disturbance on esophagogram without structural abnormality (possible achalasia). KEY RESULTS: Seven subjects were clinically relevant, including two subjects with early achalasia, four subjects with variant achalasia, and one subject with possible achalasia. All clinically relevant subjects had IRP 20 mm Hg or above. Among subjects (n = 122) with IRP 20 mm Hg or more, clinically relevant group (n = 7) had significantly higher rate of dysphagia (100% vs 24.3%, P < .001) and compartmentalized pressurization (85.7% vs 21.7%, P = .001) compared to clinically non-relevant group (n = 115). CONCLUSIONS & INFERENCES: Our results suggest that IRP of 20 mm Hg or higher could segregate clinically relevant subjects showing EGJOO in Sandhill HRM. Additionally, if subjects have both dysphagia and compartmentalized pressurization, careful follow-up is essential.


Subject(s)
Esophageal Achalasia/diagnosis , Esophagogastric Junction/physiopathology , Manometry , Aged , Deglutition Disorders/complications , Deglutition Disorders/diagnosis , Deglutition Disorders/physiopathology , Esophageal Achalasia/complications , Esophageal Achalasia/physiopathology , Female , Humans , Male , Middle Aged , Pressure
3.
Dis Esophagus ; 30(12): 1-7, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-28881892

ABSTRACT

This study aims to assess the influence of esophagectomy with gastric transposition on the gastroesophageal reflux (GER) and gastric acidity in patients with esophageal cancer. Data on 53 esophageal cancer patients who underwent 24-hour impedance-pH monitoring after esophagectomy were retrospectively analyzed. We used a solid-state esophageal pH probe in which the esophageal pH sensor is placed 1.5 cm distal to the upper esophageal sphincter and the gastric pH sensor is located 15 cm distal to the esophageal pH channel. 24-hour impedance-pH monitoring data and other clinical data including anastomosis site stricture and incidence of pneumonia were collected. We defined pathologic reflux with reference to known normative data. Stricture was defined when an intervention such as bougienage or balloon dilatation was required to relieve dysphagia. The esophageal and gastric mean pH were 5.47 ± 1.51 and 3.33 ± 1.64, respectively. The percent time of acidic pH (<4) was 6.66 ± 12.49% in the esophagus and 70.53 ± 32.19% in the stomach. Esophageal pathologic acid reflux was noticed in 32.1%, 20.8%, and 35.8% during total, upright, and recumbent time, respectively. Esophageal pathologic bolus reflux was noted in 83.0%, 77.4%, and 64.2% during total, upright, and recumbent time, respectively. Gastric acidity increased with time after esophagectomy. Esophageal acid exposure time correlated with intragastric pH. However, esophageal pathologic acid reflux was not associated with anastomosis site stricture or pneumonia. In conclusion, GER frequently occurs after esophagectomy. Thus, strict lifestyle modifications and acid suppression would be necessary in patients following esophagectomy.


Subject(s)
Esophageal Neoplasms/surgery , Esophagectomy/adverse effects , Esophagoplasty/adverse effects , Esophagus/surgery , Gastroesophageal Reflux/etiology , Stomach/surgery , Aged , Anastomosis, Surgical/adverse effects , Esophageal Stenosis/etiology , Esophageal pH Monitoring , Female , Gastric Juice/chemistry , Humans , Hydrogen-Ion Concentration , Male , Middle Aged , Pneumonia, Aspiration/etiology , Posture , Retrospective Studies , Risk Factors
4.
Aliment Pharmacol Ther ; 45(2): 345-353, 2017 01.
Article in English | MEDLINE | ID: mdl-27859470

ABSTRACT

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis. AIM: To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD. METHODS: A total of 26 540 asymptomatic adults who underwent same day first-time colonoscopy and abdominal ultrasonography as a health check-up programme were analysed. NAFLD was diagnosed by ultrasonography. Advanced colorectal neoplasia was defined as an invasive cancer or adenoma that was at least 10 mm in diameter, had high-grade dysplasia, or had villous histological characteristics or any combination thereof. RESULTS: NAFLD patients had a higher prevalence of any colorectal neoplasia (38.0% vs. 28.9%) and advanced colorectal neoplasia (2.8% vs. 1.9%) compared to those without NAFLD. In a multivariable model adjusted for age, sex, smoking, alcohol, body mass index, first-degree family history of colorectal cancer, aspirin use and metabolic factors, the odd ratios comparing patients with NAFLD to those without were 1.10 [95% confidence interval (CI): 1.03-1.17] for any colorectal neoplasia and 1.21 (95% CI: 0.99-1.47) for advanced colorectal neoplasia. When NAFLD patients were further stratified according to the non-invasive parameters of liver disease severity, the risk of any colorectal neoplasia or advanced colorectal neoplasia was higher for those with severe liver diseases than those with mild liver diseases. CONCLUSIONS: The presence and severity of NAFLD were closely associated with any colorectal neoplasia and advanced colorectal neoplasia, suggesting that clinicians should be aware of the increased risk of colorectal neoplasia in patients with NAFLD.


Subject(s)
Adenoma/epidemiology , Colorectal Neoplasms/epidemiology , Non-alcoholic Fatty Liver Disease/epidemiology , Adenoma/diagnosis , Adenoma/diagnostic imaging , Adult , Colonoscopy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/diagnostic imaging , Female , Humans , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/diagnosis , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Odds Ratio , Prevalence , Risk Factors , Ultrasonography
5.
Br J Surg ; 102(11): 1394-401, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26313295

ABSTRACT

BACKGROUND: Whether rescue surgery confers a survival benefit in patients undergoing non-curative endoscopic resection of early gastric cancer remains controversial. METHODS: This was a retrospective review of patients who underwent non-curative endoscopic resection of at least one lesion of differentiated-type early gastric cancer between 2000 and 2011. Patients with a positive lateral resection margin as the only non-curative factor were excluded. Outcome was investigated by univariable (Kaplan-Meier) and multivariable (Cox proportional hazards) analysis. RESULTS: Some 341 patients underwent non-curative endoscopic resection for at least one lesion of differentiated-type early gastric cancer. Sixty-seven patients with a positive lateral resection margin as the only non-curative factor were excluded, leaving 274 patients for analysis; 194 had rescue surgery and 80 had no additional treatment. The median duration of follow-up was 60·5 months. Patients who had rescue surgery were younger, had a lower Charlson co-morbidity index score, smaller tumours and a higher lymphovascular invasion rate than patients with no treatment. Among 194 patients who had rescue surgery, intragastric local residual tumours were found in ten (5·2 per cent) and lymph node metastases in 11 (5·7 per cent). Patients with lymph node metastasis were significantly older than those without metastasis; no other significant differences were found. Univariable analysis showed that patients aged less than 65 years, those with a Charlson co-morbidity index score below 4 and patients undergoing rescue surgery had significantly longer overall survival. Five-year overall survival rates in the rescue surgery and no-treatment groups were 94·3 and 85 per cent respectively. In multivariable analysis, rescue surgery was identified as the only independent predictor of overall survival after non-curative endoscopic resection of early gastric cancer. CONCLUSION: Rescue surgery confers a survival benefit after non-curative endoscopic resection of early gastric cancer.


Subject(s)
Gastrectomy , Gastric Mucosa/surgery , Gastroscopy , Salvage Therapy , Stomach Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Gastric Mucosa/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Reoperation , Retrospective Studies , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Survival Analysis , Treatment Outcome
6.
Neurogastroenterol Motil ; 27(5): 705-16, 2015 May.
Article in English | MEDLINE | ID: mdl-25809913

ABSTRACT

BACKGROUND: Probiotics can be beneficial in irritable bowel syndrome (IBS). Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non-diarrheal-type IBS. METHODS: Two hundred and eighty-five IBS patients were randomly assigned to either a combination of probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride at one of four different doses or a placebo for 4 weeks. The primary outcome was the proportion of patients experiencing adequate relief (AR) of global IBS symptoms at week 4. The secondary outcomes included subject's global assessment (SGA) of IBS symptom relief, individual symptoms, stool parameters, and IBS-quality of life. KEY RESULTS: The proportion of AR at week 4 was significantly higher in all treatment groups compared to the placebo group (53.7% in group 1, 55.0% in group 2, 55.2% in group 3, 53.6% in group 4 [the highest dose], and 35.1% in placebo group, respectively, p < 0.05). The proportion of patients reporting 'completely or considerably relieved' in the SGA was higher in the treatment groups than in the placebo group. The abdominal pain/discomfort score in the treatment group 4 was more prominently improved compared with that of the placebo group. In patients with constipation-predominant IBS, the improvements in stool frequency and consistency were significantly higher in the treatment groups 4 and 1, respectively, than those in the placebo group. CONCLUSIONS & INFERENCES: Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non-diarrheal-type IBS. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01505777).


Subject(s)
Benzamides/administration & dosage , Gastrointestinal Agents/administration & dosage , Irritable Bowel Syndrome/drug therapy , Morpholines/administration & dosage , Probiotics/administration & dosage , Quality of Life , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Adult , Bacillus subtilis , Double-Blind Method , Drug Therapy, Combination , Enterococcus faecium , Female , Gastrointestinal Motility , Humans , Irritable Bowel Syndrome/complications , Male , Middle Aged , Treatment Outcome
7.
Dis Esophagus ; 28(2): 145-50, 2015.
Article in English | MEDLINE | ID: mdl-24571425

ABSTRACT

The purpose of this study was to determine the effects of age, sex, body mass index (BMI), viscosity, and volume on esophageal motility using high-resolution manometry (HRM). Manometric studies were performed on 60 asymptomatic volunteers (27 men and 33 women, age: 19-56 years) while in a supine position. Manometric protocol included 10 water swallows (5 cc), 10 jelly swallows (5 cc), and 1 water swallow (20 cc). Evaluation of HRM parameters including length of proximal pressure trough (PPT length), distal latency (DL), contractile front velocity (CFV), distal contractile integral (DCI), and 4-second integrated relaxation pressure (IRP) was performed using MATLAB. Significant differences were noted in median IRP between water 5 cc (median 7.2 mmHg [range 5.5-9.6]), jelly 5 cc (median 6.0 mmHg [range 3.8-8.0]), and water 20 cc {(Median 4.8 mmHg [range 3.3-7.4]), P < 0.01}. DL were significantly different between water 5 cc, jelly 5 cc, and water 20 cc (P < 0.01), and in terms of PPT, proportions of small (2 cm ≤ < 5 cm) and large (5 cm≤) break for jelly 5 cc were significantly higher than those for the water 5 cc swallow (P < 0.05). Furthermore, DCI increased with age for water 5 cc, and a significant negative correlation was noticed between proportions of small break and BMI for water 5 cc. Manometric measurements vary depending on age, BMI, viscosity, and volume. These findings need to be taken into account in the interpretation of manometry results.


Subject(s)
Deglutition/physiology , Esophagus/physiology , Peristalsis/physiology , Adult , Age Factors , Body Mass Index , Drinking Water , Esophageal Motility Disorders/diagnosis , Female , Gelatin/administration & dosage , Humans , Male , Manometry/methods , Middle Aged , Muscle Contraction , Pressure , Sex Factors , Supine Position , Viscosity
8.
Aliment Pharmacol Ther ; 40(6): 695-704, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25078671

ABSTRACT

BACKGROUND: The risk of spontaneous bacterial peritonitis (SBP) associated with proton pump inhibitor (PPI) use has been raised in cirrhotic patients with ascites. However, this is based on case-control studies, often with a small series. AIM: To determine whether PPI use increases the risk of SBP using a large cohort. METHODS: This retrospective cohort study included 1965 cirrhotic patients with ascites diagnosed between January 2005 and December 2009. The SBP incidence rate was compared between the PPI and non-PPI groups before and after propensity score matching to reduce the effect of selection bias and potential confounders. Multivariate analysis was conducted to confirm the association of PPI use with SBP. RESULTS: After excluding 411 patients, 1554 were analysed. Among them, 512 patients (32.9%) were included in the PPI group. The annual SBP incidence rate was higher in the PPI group than in the non-PPI group (10.6% and 5.8%, P = 0.002) before matching. Indications for PPI use and dose of PPI were similar between patients with and without SBP. In the propensity score matched cohort (402 pairs), the SBP incidence rate was also higher in the PPI group than in the non-PPI group (10.8% vs. 6.0%, P = 0.038). Multivariate analysis revealed that PPI use (Hazard ratio 1.396; 95% confidence interval, 1.057-1.843; P = 0.019) was the independent risk factor for SBP. CONCLUSIONS: Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Proton pump inhibitor use should be undertaken with greater caution and appropriately in patients with cirrhosis.


Subject(s)
Ascites/complications , Bacterial Infections/complications , Liver Cirrhosis/complications , Peritonitis/complications , Proton Pump Inhibitors/adverse effects , Aged , Ascites/epidemiology , Bacterial Infections/epidemiology , Female , Humans , Liver Cirrhosis/epidemiology , Male , Middle Aged , Peritonitis/epidemiology , Propensity Score , Retrospective Studies
9.
Neurogastroenterol Motil ; 26(2): 229-36, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24165095

ABSTRACT

BACKGROUND: Little has been known about the contractile characteristics of diabetic stomach. We investigated spontaneous contractions and responses to acetylcholine in the gastric muscle in diabetic patients and non-diabetic control subjects according to the region of stomach. METHODS: Gastric specimens were obtained from 26 diabetics and 55 controls who underwent gastrectomy at Samsung Medical Center between February 2008 and November 2011. Isometric force measurements were performed using circular muscle strips from the different regions of stomach under basal condition and in response to acetylcholine. KEY RESULTS: Basal tone of control was higher in the proximal stomach than in the distal (0.63 g vs 0.46 g, p = 0.027). However, in diabetics, basal tone was not significantly different between the proximal and distal stomach (0.75 g vs 0.62 g, p = 0.32). The distal stomach of diabetics had higher basal tone and lower frequency than that of control (0.62 g vs 0.46 g, p = 0.049 and 4.0/min vs 4.9/min, p = 0.049, respectively). After exposure to acetylcholine, dose-dependent increases of basal tone, peak, and area under the curve (AUC) were noticed in both proximal and distal stomach of the two groups. In the proximal stomach, however, the dose-dependent increase of basal tone and AUC was less prominent in diabetics than in control. CONCLUSIONS & INFERENCES: On the contrary to control, the proximal to distal tonic gradient was not observed in diabetic stomach. Diabetic stomach also had lower frequency of spontaneous contraction in the distal stomach and less acetylcholine-induced positive inotropic effect in the proximal stomach than control.


Subject(s)
Diabetes Mellitus/physiopathology , Muscle Contraction/physiology , Stomach/physiopathology , Acetylcholine/pharmacology , Age Factors , Aged , Female , Humans , Male , Muscle Contraction/drug effects , Sex Factors , Stomach/drug effects
10.
Endoscopy ; 45(7): 575-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23801315

ABSTRACT

We present 19 cases in which argon plasma coagulation (APC) was used as curative initial treatment for 5 low-grade esophageal squamous intraepithelial neoplasias (ESINs), 12 high-grade ESINs, and 2 early esophageal squamous cell carcinomas (ESCCs). Complete response was defined as the absence of tumor from any biopsy taken from the ablated lesion. At follow-up endoscopy 2 - 4 months after APC, 94.7 % of patients had achieved complete response in a single treatment session. Only one patient with high-grade ESIN showed local recurrence. This patient underwent additional APC and showed complete response at 12 months after initial APC. At the 12-month follow-up endoscopy, again 94.7 % had a complete response. The exception was one patient with local recurrence, who underwent additional APC. After the 12-month follow-up endoscopy, no patient showed local recurrence during a median follow-up of 22 months. No stricture requiring endoscopic dilation occurred after the procedure. This study suggests that APC is a feasible and effective treatment modality for ESIN and early ESCC.


Subject(s)
Argon Plasma Coagulation , Carcinoma, Squamous Cell/surgery , Esophageal Neoplasms/surgery , Precancerous Conditions/surgery , Aged , Argon Plasma Coagulation/instrumentation , Argon Plasma Coagulation/methods , Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Esophagoscopy , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Precancerous Conditions/pathology , Retrospective Studies , Treatment Outcome
11.
Endoscopy ; 44(10): 949-52, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22987215

ABSTRACT

Extremely well-differentiated tubular adenocarcinomas (EWDAs) of the stomach are characterized by surface maturation and their mimicking of intestinal metaplasia. Endoscopically, intramucosal EWDAs are frequently ill defined with indistinct borders due to the pallor of the neoplastic mucosa and the lack of contrast against the background atrophic and metaplastic mucosa. We evaluated the effectiveness of endoscopic resection for EWDAs after endoscopic submucosal dissection (ESD). Among 872 patients with early gastric cancer, 17 EWDAs were identified (1.9 %). Endoscopically, the flat or depressed type was significantly more common among EWDAs (88.2 %) than among early gastric cancers of other histologies (37.8 %; P < 0.01). The discrepancy between endoscopically estimated tumor size and tumor size as confirmed in pathology reports was significantly greater among EWDAs (18.4 ±â€Š22.0  mm) than among others (5.8 ±â€Š7.5  mm). Involvement of the lateral resection margin was more common (29.4 % vs. 2.5 %; P < 0.05), and complete resection was achieved less often in EWDAs (47.1 % vs. 80.4 %; P = 0.01) compared to the others. EWDAs are associated with higher rates of incomplete resection after ESD, especially along the lateral margins. Pathologists should alert endoscopists when this diagnosis is made, with its associated risks; and endoscopists should pay particular attention to the extent of these tumors during resection.


Subject(s)
Adenocarcinoma/surgery , Gastric Mucosa/surgery , Gastroscopy/methods , Stomach Neoplasms/surgery , Adenocarcinoma/pathology , Female , Gastric Mucosa/pathology , Humans , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/pathology , Treatment Outcome
12.
Neurogastroenterol Motil ; 23(12): 1098-104, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21920001

ABSTRACT

BACKGROUND: The 5-HT(3) receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT(3) receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). METHODS: This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5µg once daily or a 4-week treatment of mebeverine 135 mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. KEY RESULTS: The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. CONCLUSIONS & INFERENCES: Ramosetron 5µg once daily is as effective as mebeverine three times daily in male patients with IBS-D.


Subject(s)
Benzimidazoles/therapeutic use , Diarrhea/drug therapy , Irritable Bowel Syndrome/drug therapy , Parasympatholytics/therapeutic use , Phenethylamines/therapeutic use , Serotonin 5-HT3 Receptor Antagonists/therapeutic use , Adolescent , Adult , Diarrhea/etiology , Diarrhea/physiopathology , Humans , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/physiopathology , Male , Middle Aged , Republic of Korea , Treatment Outcome , Young Adult
13.
Endoscopy ; 42(9): 699-704, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20806154

ABSTRACT

BACKGROUND AND STUDY AIM: The establishment of precise and valid diagnostic criteria is important for any disease. We determined the interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus. PATIENTS AND METHODS: Video clips of endoscopy in 21 patients with/without Barrett's esophagus were used for training (n = 3) and for diagnosis/grading (n = 18) of Barrett's esophagus by endoscopists from seven hospitals in Asia. Barrett's esophagus was graded using the Prague C & M Criteria whereby the circumferential extent of the Barrett's segment (C value), maximum extent of Barrett's segment (M value), location of the gastroesophageal junction, and location of the diaphragmatic hiatus were scored. The intraclass correlation coefficients (ICC) were calculated as a measure of interobserver reliability. RESULTS: A total of 34 endoscopists participated. ICC values for the scores of the C value, M value, location of the gastroesophageal junction, and location of the diaphragmatic hiatus were: 0.92 (95 % confidence interval [CI] 0.88 - 0.97), 0.94 (95 %CI 0.90 - 0.98), 0.86 (95 %CI 0.78 - 0.94), and 0.81 (95 %CI 0.71 - 0.92), respectively, indicating excellent interobserver agreement. The differences in region/country, endoscopists' experience, case volume of participating centers, or primary practice type had no significant effect on the reliability. The ICC values for recognition of Barrett's esophagus of > or = 1 cm were 0.90 (95 %CI 0.80 - 1.00) and 0.92 (95 %CI 0.87 - 0.98) for the C and M values, respectively, whereas the corresponding ICC values for Barrett's segment of < 1 cm were 0.18 (95 %CI 0.03 - 0.32) and 0.21 (95 %CI 0.00 - 0.51), respectively. CONCLUSIONS: Despite the uncommon occurrence of Barrett's esophagus in Asia, our endoscopists exhibited excellent agreement in the endoscopic diagnosis and grading of Barrett's esophagus using the Prague C & M Criteria. However, in view of the low interobserver reliability in recognizing Barrett's segments of < 1 cm, future studies in Asia should take this into account when selecting the study population.


Subject(s)
Barrett Esophagus/pathology , Clinical Competence/statistics & numerical data , Esophagoscopy/standards , Asia , Barrett Esophagus/diagnosis , Humans , Observer Variation , Reproducibility of Results
14.
Dig Liver Dis ; 41(5): 328-37, 2009 May.
Article in English | MEDLINE | ID: mdl-18976971

ABSTRACT

BACKGROUND: 5-Aminosalicylic acid lacks the well-known side effects associated with the long-term use of non-steroidal anti-inflammatory drugs. We investigated anti-carcinogenic mechanisms of 5-aminosalicylic acid on a colon cancer cell line. METHODS: MTT analysis was performed for various colon cancer cell lines. The expression of NF-kappaB and metalloproteinases was examined in either HT-29 cells treated with IL-1beta and/or 5-aminosalicylic acid. Matrigel assay was used to evaluate invasive potential of HT-29 cells. Analysis of a cDNA microarray containing 8700 genes was performed to identify the alteration of gene expression in response to treatment to 5-aminosalicylic acid. RESULTS: The use of MTT analysis showed that 5-aminosalicylic acid suppressed the growth of HT-29 cells. The activity of NF-kappaB was also decreased by combined-treatment with IL-1beta and 5-aminosalicylic acid. The use of an ELISA and zymography demonstrated that MMP-2 and MMP-9 enzyme activity were decreased in HT-29 cells by treatment with various concentration of 5-aminosalicylic acid. A matrigel analysis demonstrated that 5-aminosalicylic acid treatment on HT-29 significantly inhibited the invasiveness of the cells. In cDNA microarray, 163 genes following 5-aminosalicylic acid exposure showed altered expression. CONCLUSIONS: This study indicated that 5-aminosalicylic acid suppresses the growth of human colon cancer cells and is able to inhibit MMPs expression via NF-kappaB mediated cell signals and invasiveness.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Colonic Neoplasms/pathology , Colonic Neoplasms/prevention & control , Mesalamine/administration & dosage , Cell Proliferation/drug effects , Colonic Neoplasms/enzymology , Down-Regulation/drug effects , Gene Expression/drug effects , HT29 Cells , Humans , Metalloproteases/drug effects , Metalloproteases/genetics , NF-kappa B/drug effects , Neoplasm Invasiveness/prevention & control , Oligonucleotide Array Sequence Analysis
15.
Dig Liver Dis ; 41(3): 201-9, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18571998

ABSTRACT

BACKGROUND: To achieve en bloc resection for large lesions, endoscopic mucosal resection after circumferential precutting and endoscopic submucosal dissection techniques have been developed. AIM: To compare endoscopic submucosal dissection with endoscopic mucosal resection after circumferential precutting in terms of the clinical efficacy and safety. PATIENTS AND METHODS: 346 consecutive patients underwent their first endoscopic mucosal resection after circumferential precutting (103 patients) or endoscopic submucosal dissection (243 patients) for early gastric cancer and their clinical outcomes were compared. RESULTS: For early gastric cancer >or=20mm endoscopic submucosal dissection group demonstrated significantly higher en bloc resection and en bloc plus R0 resection rate compared with endoscopic mucosal resection after circumferential precutting group. For early gastric cancer with size of 10-19 mm, endoscopic submucosal dissection group also showed significantly higher en bloc resection rate. For early gastric cancer <20mm, however, en bloc plus R0 resection rate for endoscopic mucosal resection after circumferential precutting group was comparable to that for endoscopic submucosal dissection group. In case of R0 resection of intramucosal differentiated cancer, neither group showed local recurrence during the median 29 and 17 months of follow-up. Two groups did not show significant difference in the bleeding or perforation rates. CONCLUSION: For early gastric cancer <20mm endoscopic mucosal resection after circumferential precutting may be considered as an alternative choice to endoscopic submucosal dissection. However, for early gastric cancer >or=20mm endoscopic submucosal dissection should be considered as the first choice for treating early gastric cancer.


Subject(s)
Gastric Mucosa/surgery , Gastroscopy/methods , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Adenoma/pathology , Adenoma/surgery , Adult , Aged , Aged, 80 and over , Electrosurgery , Female , Gastric Mucosa/pathology , Gastroscopy/adverse effects , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Retrospective Studies
16.
Endoscopy ; 40(6): 472-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18543135

ABSTRACT

BACKGROUND AND STUDY AIMS: After upper endoscopy, patients have complained of symptoms involving teeth or the temporomandibular joint; however, these endoscopy-related complications are usually ignored with few attempts to prevent them. The aim of this study was to identify the incidence of endoscopy-related complications involving teeth or temporomandibular joint, and to compare the effectiveness of a newly developed teeth-protecting mouthpiece (TPM) with a traditional mouthpiece (the MB-142) in preventing these complications. PATIENTS AND METHODS: 872 patients from 28 centers, who were undergoing their first upper endoscopy, were randomly assigned to TPM and MB-142 groups. At 3 - 4 days after the procedure, the occurrence of endoscopy-related complications involving the teeth or the temporomandibular joint was investigated using a structured questionnaire. Finally 865 patients (TPM group, n = 423; MB-142, n = 442) responded to this questionnaire and were included in the analysis. RESULTS: Overall, the incidence of complications was significantly lower in the TPM than in the MB-142 group (0.9% vs. 3.2%). With stratification according to sedation status, in nonsedated patients no significant difference was found between the two groups (0.7% vs. 0.9%). In sedated patients, however, the TPM group showed a significantly lower incidence of complication than the MB-142 group (1.7% vs. 11.6%). Clinically serious problems such as a tooth fracture or a loose tooth occurred only in sedated patients in the MB-142 group. CONCLUSIONS: The TPM showed an advantage over the MB-142 mouthpiece for preventing endoscopy-related complications involving teeth or the temporomandibular joint.


Subject(s)
Endoscopy, Digestive System/adverse effects , Mouth Protectors/standards , Temporomandibular Joint Disorders/prevention & control , Tooth Diseases/prevention & control , Adult , Aged , Endoscopy, Digestive System/methods , Equipment Design , Equipment Safety , Esophagoscopy/adverse effects , Esophagoscopy/methods , Gastroscopy/adverse effects , Gastroscopy/methods , Humans , Middle Aged , Mouth Protectors/statistics & numerical data , Reference Values , Sensitivity and Specificity , Temporomandibular Joint Disorders/etiology , Tensile Strength , Tooth Diseases/etiology
17.
Aliment Pharmacol Ther ; 27(12): 1275-81, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18315581

ABSTRACT

BACKGROUND: Although the aetiology of globus (the sensation of a lump in the throat) remains unclear, gastro-oesophageal reflux disease is associated with globus. A short-term trial with a high-dose proton pump inhibitor has been shown to be a sensitive tool for diagnosing gastro-oesophageal reflux disease. AIM: To see whether patients with globus symptom responded to short-term high-dose rabeprazole trial and assess predictors of symptom response. METHODS: Sixty-four patients with globus symptom were analysed. Patients received rabeprazole 20 mg b.d. for 14 days. Patients completed a daily diary assessing the severity and frequency of globus. RESULTS: Forty-one patients (64%) were diagnosed clinically with gastro-oesophageal reflux disease. Based on the pH testing and endoscopy, the prevalence of gastro-oesophageal reflux disease was 22% (14 of 64). The globus symptom score was significantly higher in patients with gastro-oesophageal reflux disease compared with patients without gastro-oesophageal reflux disease (P = 0.004). Two patients (3%) had complete resolution and 22 (34%) had more than a 50% improvement in the globus symptom score. Endoscopic findings (P = 0.714), pathological acid exposure on pH testing (P = 0.741) or baseline gastro-oesophageal reflux disease symptoms (P = 0.606) were not associated with improvement of globus symptom. CONCLUSION: While gastro-oesophageal reflux disease may be an aggravating factor in patients with globus, it does not appear to be the sole cause of globus symptom.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , Anti-Ulcer Agents/administration & dosage , Gastroesophageal Reflux/drug therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Rabeprazole
18.
Endoscopy ; 39(2): 156-60, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17657701

ABSTRACT

BACKGROUND AND STUDY AIMS: Primary NK-/T-cell lymphoma of the gastrointestinal tract is a very rare disease with a poor prognosis. The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-cell lymphoma. PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-cell lymphoma and the endoscopic findings in 11 of these patients were reviewed. Their median age was 42 years (range 23-78) at the time of diagnosis. RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-cell lymphoma were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%). The disease was at an advanced stage at the time of diagnosis: stage II in 5 patients (36%); stage III in 4 (28%); and stage IV in 5 (36%). Initial treatment was with chemotherapy (n = 8, 57%) or surgical resection (n = 5, 36%). The median survival for all patients was 9 months. On endoscopy in 11 patients, the anatomic location of the primary lesion was found to be: stomach, n = 3 (27%); esophagus, n = 2 (18%); duodenum, n = 1 (9%); and the ileocolonic area, n = 5 (46%). These lesions were ulceroinfiltrative in 4 cases (36%), ulcerative in 3 cases (27%), superficial/erosive in 3 cases (27%), and infiltrative in 1 case (9%). No prominent fungating mass was seen in any patient. CONCLUSIONS: Primary gastrointestinal NK-/T-cell lymphoma was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass. The most common presenting symptom was gastrointestinal bleeding. Despite aggressive treatments, the prognosis was very poor.


Subject(s)
Endoscopy, Gastrointestinal , Gastrointestinal Neoplasms/pathology , Killer Cells, Natural/pathology , Lymphoma, T-Cell/pathology , Adult , Aged , Female , Flow Cytometry , Humans , Immunohistochemistry , In Situ Hybridization , Male , Middle Aged , Survival Analysis
19.
Dig Liver Dis ; 38(8): 605-8, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16824812

ABSTRACT

BACKGROUND: Perforation and bleeding are major complications associated with gastric endoscopic mucosal resection. Evident perforation during endoscopic mucosal resection can be managed by endoscopic clipping. However, management of microperforation is not well established. PATIENT AND METHOD: From January 2002 to June 2004, 109 early gastric cancers and 300 adenomas were treated with endoscopic mucosal resection. Iatrogenic perforations occurred in 4.16% (n=17) patients. Following exclusion of four evident perforations, microperforation was observed in 3.18% (n=13) patients. The clinical features of microperforation in patients were retrospectively reviewed. RESULTS: In a total of 13 microperforation cases, 2 patients were managed surgically. The remaining patients successfully recovered without surgical management. In the case of 11 patients without surgery, 7 experienced abdominal pain, which required analgesics, 2 patients experienced mild discomfort and 2 patients experienced no symptoms. A body temperature above 37.5 degrees C was observed in 9.1% (n=1) patients and leucocytosis above 9000 microL-1 was in 72.7% (n=8) patients. The mean duration of nasogastric tube drainage was 2.36+/-1.03 days, of fasting 4.18+/-1.17 days, of intravenous antibiotics 5.55+/-1.44 days and of hospitalisation 7.45+/-1.04 days. CONCLUSION: Microperforation induced by gastric endoscopic mucosal resection can be managed successfully using a non-surgical approach including fasting, nasogastric tube drainage and intravenous antibiotics.


Subject(s)
Gastric Mucosa/surgery , Gastroscopy/adverse effects , Intestinal Perforation/etiology , Intestinal Perforation/therapy , Abdominal Pain/etiology , Abdominal Pain/therapy , Adenoma/surgery , Aged , Aged, 80 and over , Analgesics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Drainage , Fasting , Female , Follow-Up Studies , Gastric Mucosa/pathology , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Hospitalization , Humans , Intubation, Gastrointestinal , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/surgery , Treatment Outcome
20.
Neurogastroenterol Motil ; 18(7): 539-46, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16771769

ABSTRACT

The objective of this study was to determine whether or not the number of enteroendocrine cells (ECs) in the gut is related to visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). Twenty-five subjects with D-IBS (mean, 43.1 years; 16 women, nine men) were recruited into our study, along with 13 healthy controls (mean, 40.7 years; nine women, four men). Maximally tolerable pressures were evaluated via barostat testing, and the levels of ECs were immunohistochemically identified and quantified via image analysis. The numbers of ECs between the D-IBS subjects and the controls were not significantly different in the terminal ileum, ascending colon and rectum. However, the maximally tolerable pressures determined in the D-IBS subjects were significantly lower than those of the control subjects (P < 0.01), and we detected a significant relationship between the maximally tolerable pressures and the numbers of ECs in the rectum (r = -0.37, P < 0.01). Rectal sensitivity was enhanced to a greater degree in D-IBS patients exhibiting an elevated level of rectal ECs. This study provides some evidence to suggest that ECs play an important role in visceral hypersensitivity.


Subject(s)
Enteroendocrine Cells/cytology , Intestinal Mucosa/cytology , Irritable Bowel Syndrome/physiopathology , Adult , Cell Count , Diarrhea/etiology , Female , Humans , Immunohistochemistry , Irritable Bowel Syndrome/complications , Male , Manometry , Pain Threshold , Surveys and Questionnaires , Viscera/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...